Losartan and Gabapentin Interaction: Safety, Risks, and Clinical Guidance

Losartan (brand name Cozaar) is an angiotensin II receptor blocker (ARB) used for hypertension, certain heart failure regimens, and diabetic nephropathy. Gabapentin (brand names Neurontin, Gralise, Horizant) is an anticonvulsant used off-label and on-label for neuropathic pain, postherpetic neuralgia, and seizures. They are frequently taken together because diabetic patients often need an ARB for blood pressure and kidney protection and gabapentin for peripheral neuropathy.

The direct answer

There is no known pharmacokinetic conflict between losartan and gabapentin. Gabapentin is eliminated unchanged by the kidneys and does not undergo hepatic metabolism, so it does not compete with losartan for CYP2C9/CYP3A4 conversion to its active metabolite (E-3174), and it is minimally protein-bound so it does not displace losartan from albumin. The interaction that matters in practice is additive: both drugs can independently cause blood pressure lowering, dizziness, or sedation, and combining them can make orthostatic symptoms more noticeable, especially in patients who are also volume-depleted, elderly, or have declining kidney function. This is a monitor-level interaction, not an avoid-level one, in the drug-interaction resources clinicians commonly use, though specific severity ratings should be confirmed in the reviewer's current Lexicomp, Micromedex, or Clinical Pharmacology subscription rather than assumed from this summary.

Why this combination comes up so often

Type 2 diabetes commonly produces both hypertension, which is frequently treated with an ARB such as losartan for its blood pressure and renal-protective effects, and peripheral neuropathy, which is frequently treated with gabapentin. That overlap in the diabetic population is the main reason clinicians see this pairing repeatedly. It reflects two drugs treating two different problems in the same patient, not an inherent pharmacologic pairing that was designed together.

What is pharmacokinetically established

• Losartan is metabolized primarily by CYP2C9, with a minor contribution from CYP3A4, to the more pharmacologically active carboxylic acid metabolite. It is highly protein-bound.
• Gabapentin undergoes essentially no hepatic metabolism, is not a substrate, inhibitor, or inducer of the CYP450 system at clinical exposures, and is excreted by the kidneys largely unchanged. Its own FDA-approved prescribing information notes that gabapentin does not appreciably interfere with the metabolism of commonly co-administered drugs.

Because the two drugs are cleared through unrelated systems, the well-characterized routes for a true pharmacokinetic drug interaction (shared CYP enzymes, protein-binding displacement, competing transporters) are not present here. This is an established point, not a modeled one, and it is why neither drug's label lists the other as a metabolic interaction concern.

What is pharmacologically plausible but not well quantified

Losartan lowers blood pressure by blocking the AT1 receptor, reducing vascular resistance and aldosterone secretion. Gabapentin is not an antihypertensive, but some observational and small clinical reports describe modest blood-pressure-lowering or sedative/dizziness effects, plausibly related to its binding at the alpha-2-delta subunit of central voltage-gated calcium channels. If both effects are present in the same patient at the same time, additive hypotension and additive CNS depression (drowsiness, unsteadiness) are pharmacologically plausible.

What is not solid, based on the material available for this review, is a precise, verified effect size for gabapentin's blood-pressure effect or a dedicated interaction trial quantifying the combined drop in blood pressure or fall risk when the two drugs are used together. Older drafts of this topic have circulated specific numbers (exact mmHg reductions, hazard ratios, trial patient counts) attributed to named studies; those figures could not be verified against a located, on-topic primary source during this review and have been removed rather than repeated. A clinician who wants a specific number for a specific claim should pull the primary study directly rather than rely on a secondary summary.

Shared renal vulnerability

Both drugs interact with the kidney, but through different mechanisms, and this is where a slow-moving interaction can develop over weeks rather than hours.

• Losartan reduces glomerular filtration pressure through efferent arteriolar dilation. A drop in eGFR after starting or increasing an ARB is a recognized, expected pharmacologic effect in many patients, not necessarily a sign of harm, but it needs to be tracked.
• Gabapentin's clearance is essentially proportional to creatinine clearance. The FDA label provides renal dose-adjustment tiers based on creatinine clearance for this reason.

If losartan produces even a modest reduction in eGFR in a patient whose kidney function was already reduced, gabapentin clearance can fall in parallel, raising the risk of gabapentin accumulation, sedation, or ataxia at a dose the patient had previously tolerated. This mechanism is well established pharmacologically. What is not established from the sources available here is a specific quantitative threshold at which this becomes clinically significant for a given patient; that judgment depends on baseline renal function, other nephrotoxic exposures, and trend over time, and should be made by the prescriber using the patient's own labs.

Evidence-status interaction assessment

Monitoring approach if both are prescribed

This is a site-judgment framework, not a substitute for individualized dosing decisions, which should come from the prescriber.

Early phase (first one to two weeks after starting or changing either drug):

• Home blood pressure checks, both seated and standing, to catch orthostatic drops
• Counseling on standing up slowly and recognizing lightheadedness
• Attention to unusual drowsiness or unsteady gait, particularly in the hours after a gabapentin dose

Around one to two weeks in:

• Basic metabolic panel including creatinine and potassium, with eGFR compared to baseline
• If eGFR has fallen meaningfully from baseline, the prescriber may pause any planned losartan uptitration pending reassessment of volume status and renal trend

Ongoing:

• Periodic blood pressure and renal function checks, with frequency set by the prescriber based on baseline kidney function and stability
• Reassessment of whether gabapentin is still needed, since neuropathic symptoms can change over time

Any specific dose, dose-adjustment amount, or titration schedule should come from the prescriber based on the individual's renal function, blood pressure response, and tolerance. This article does not provide those numbers because they cannot be safely generalized.

Special situations worth flagging to a prescriber or pharmacist

• Older adults. Gabapentin has been associated with increased fall risk in observational research, and losartan-related orthostatic effects can compound that risk. The exact magnitude of increased risk from combined use specifically has not been confirmed here and should be discussed with the prescriber rather than assumed.
• Patients also taking a diuretic. Adding a diuretic to losartan and gabapentin increases the chance of symptomatic low blood pressure, especially during illness with fluid loss.
• Diabetic nephropathy patients. This is the most common overlap population. Current nephrology guidance generally favors continuing RAAS blockade despite a modest eGFR decline after starting an ARB, but gabapentin dosing needs to track renal function over time in the same patient.
• Intermittent NSAID use. NSAIDs can blunt losartan's effect and further stress renal perfusion. Patients on losartan and gabapentin who add over-the-counter NSAIDs for pain create a third source of renal strain, and this combination is worth specific counseling.

What this interaction does not involve

• No known QT-prolongation interaction between the two drugs.
• No serotonergic mechanism in either drug, so this is not a serotonin syndrome concern.
• No hepatotoxicity interaction, since gabapentin is not hepatically processed.
• No direct effect on platelet function or coagulation from either agent.

These negatives are useful because they define the boundary of concern: the interaction is about blood pressure, sedation, and renal-linked clearance, not about a broader multi-system risk.

Patient-facing safety points

• Ask your prescriber or pharmacist before starting either drug if you are already taking the other one.
• Report new dizziness on standing, unusual drowsiness, or unsteady walking, particularly in the first two weeks after a dose change.
• Avoid alcohol during dose titration, since it can worsen both the blood-pressure-lowering and sedative effects.
• Do not stop gabapentin abruptly on your own; discontinuing gabapentin requires a gradual taper because abrupt discontinuation carries a withdrawal seizure risk. Ask your prescriber how to do this safely if a change is needed.
• Losartan can generally be stopped without a taper, but blood pressure can rebound within a few days, so have a follow-up plan with your prescriber rather than stopping on your own.
• Seek urgent care for fainting, a blood pressure reading that feels dangerously low with symptoms, a fall with injury, or new confusion or severe drowsiness.

Evidence boundary

Established: No CYP450 or protein-binding interaction exists between losartan and gabapentin based on their independently documented pharmacokinetics. Gabapentin is renally cleared and requires dose adjustment for reduced kidney function, per its FDA label, independent of losartan.

Plausible but not precisely quantified from the sources reviewed here: Additive blood-pressure lowering and CNS depression when both drugs are active; a downstream rise in gabapentin exposure if losartan meaningfully reduces eGFR in a given patient.

Not established: A specific numeric magnitude for the combined effect on blood pressure or fall risk, and a universal severity rating that applies to every patient regardless of renal function and age. Any such number attached to this pairing should be checked against a current, on-topic primary source before being treated as fact.

Frequently asked questions

References

• U.S. Food and Drug Administration, FDA Adverse Event Reporting System (FAERS) Public Dashboard: https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard
• U.S. Food and Drug Administration, drug approvals and labeling database: https://www.fda.gov/drugs

Several specific citations present in earlier drafts of this topic (named trials, exact effect sizes, and a quoted expert statement) could not be verified against a located, on-topic primary source during this review and have been removed or replaced with general, hedged language rather than presented as sourced fact. A clinician or medical reviewer should confirm current severity ratings in Lexicomp or Micromedex and consult primary literature directly before any specific numeric claim is restored to this page.